







Newsletter #6

03 September 2021

Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration

Total number of cases repor	ted			59
Countries that assessed chil	dren, n			
France	38	Italy	3	
Poland	9	India	3	
Russia	4	Portugal	2	
Children				
Girls / boys				24 / 35
Age (mean ± SD)				12.3 ± 3.7 y
Psoriasis before COVID-19				
Age of onset of psoriasis	(mean ± SD)			6.5 ± 3.9 y
Plaque psoriasis				38
Nail psoriasis				30
Psoriasis arthritis				2
COVID-19				
Confirmed / suspected				51/8
N° of COVID-19 / child				
1				57
2				1
Symptoms				26
Yes				36
Hospitalization / oxyge	en tnerapy			0/0
Long-covid				1
Since COVID-19 onset, the p	soriasis has			
Improved				0
Worsened, with same	psoriasis phenotype			6
Worsened, phenotype				0
Remained same	0.1			45
Psoriasis de novo				2
No information				6
Systemic medication for pso	riasis at time of ons	et of COVID-19		
Phototherapy 4	Cyclo	sporine 1		Ustekinumab 7

You can include children with psoriasis and COVID-19 on:

Adalimumab

Etanercept

4

4

Risankizumab

1

 $https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfncx4ky8CEUILWa7veJmHb0FthGKuudaQD\\ wbCfNQ/viewform?vc=0\&c=0\&w=1\&flr=0$

Website: www.sfdermato.org/site/chi-psocov.html

Methotrexate

Acitretin

4

3